兴齐眼药(300573) - 2025年4月29日兴齐眼药投资者关系活动记录表（1）

Group 1: Company Performance - In 2024, the company achieved a revenue of CNY 1.943 billion, representing a year-on-year growth of 32.42% [4] - The total profit reached CNY 395 million, with a year-on-year increase of 49.07% [4] - The compound annual growth rate (CAGR) of revenue over the past three years is 24.70% [4] Group 2: Marketing and Sales Strategy - The company emphasizes building a stable marketing team while attracting external talent to enhance its marketing capabilities [3] - A multi-tiered marketing network has been established, covering all provinces and regions in China [3] - The marketing strategy focuses on academic promotion through meetings and seminars to disseminate product information [3] Group 3: Product Portfolio - The company specializes in ophthalmic drugs, with a product range that includes treatments for myopia, dry eye, infections, and glaucoma [6] - Currently, the company holds 60 approved ophthalmic drug licenses, with 38 products included in the medical insurance directory [6] - Key products contributing over 10% of revenue include Cyclosporine Eye Drops and Atropine Sulfate Eye Drops [6] Group 4: Research and Development - R&D investments over the past three years were CNY 190 million, CNY 181 million, and CNY 235 million, accounting for 15.22%, 12.38%, and 12.11% of revenue respectively [10] - Future R&D plans include expanding the product line in the ophthalmic sector and focusing on biologics for retinal diseases [10] Group 5: ESG Initiatives - The company aims to integrate ESG principles into its strategic planning and operations, focusing on green and low-carbon development [8] - Achievements include being recognized as a "National Green Factory" and implementing measures to reduce energy consumption and waste [9] - The company plans to enhance transparency in ESG reporting and stakeholder communication [8]